HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 22, No 01, January 2018 – Weighing the options       » Scientists close in on origin of SARS       » Chinese researchers map key protein in DNA repair with near-atomic resolution       » Ryzodeg reduces hypoglycaemia in type 2 diabetic fasting patients       » United States cancer drug costs increasing despite competition       » Eating yogurt may help reduce chronic inflammation in women      
EYE ON CHINA
Sareum enters co-development agreement in China for Aurora+FLT3 program

Sareum Holdings, a specialist cancer drug discovery and development business, has entered a co-development agreement with Hebei Medical University Biomedical Engineering Center (HMUBEC), an independent research center, to advance its Aurora+FLT3 cancer program.

Under the terms of the agreement HMUBEC has been granted exclusive rights to carry out pre-clinical and clinical studies within Greater China* to obtain approval for sales in that territory.

Aurora+FLT3 kinase inhibitors have the potential to treat acute myeloid leukaemia (AML, the most common form of adult leukaemia) and various other forms of cancer. Aurora kinase is involved in the control of mitosis (cell division), and FLT3 kinase over-activation is the most common mutation in AML. The pre-clinical development candidate that has been licenced by Sareum to HMUBEC has showed particular promise against a range of haematological cancer models including AML and Acute Lymphoblastic Leukaemia (ALL) with an encouraging early safety profile and positive ADME (absorption, distribution, metabolism, excretion) properties.

Sareum was advised and assisted on this agreement by Cambridge, UK based technology brokerage Link China Pharma Solutions.

Dr. Tim Mitchell, Chief Executive Officer of Sareum Holdings plc, said: "This agreement provides us with significant additional resource, exposure to a major market and the flexibility to undertake our own independent research utilising HMUBEC's findings at any point in the development programme. HMUBEC also has the capability and resources to advance the Aurora+FLT3 programme from pre-clinical all the way through clinical trials and onto the Chinese market. We believe all this provides a good balance of risk and reward for our shareholders and we look forward to working closely with HMUBEC."

Professor Donggang Liu, Deputy General Manager of the Hebei Medical University Science & Technology General Company, said: "We have been very impressed with the results of the studies undertaken on Sareum's Aurora+FLT3 programme so far and we have real confidence in the programme's potential to develop a world class drug to treat several forms of blood cancer. HMUBEC has significant resources and expertise to expedite this research programme, and we look forward to commencing work on this very exciting compound."

*Greater China includes the People's Republic of China, and the special administrative regions of Hong Kong and Macau, and Taiwan region.

Click here for the complete issue.

NEWS CRUNCH  
news Biology of Ageing II - Impactful Interventions
news Separation of conjoined twins presents surgical and ethical challenges for MassGeneral Hospital for Children staff
news MIT Technology Review announces 2018's 10 'Innovators Under 35 Asia'
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Addressing the ageing population / Clinical trials
March:
Nutrition / Women in Science
April:
Digestive health / Intellectual property
May:
Asthma / Dental health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy